KMS Medisurgi Limited has submitted its quarterly compliance certificate under SEBI regulations for the quarter ended 31st March, 2026. The Mumbai-based company filed the mandatory certificate with BSE Limited on 14.04.2026, fulfilling its regulatory obligations under the SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Details

The certificate was submitted pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This regulation requires companies to provide quarterly confirmations regarding the status of their share dematerialisation and any re-materialisation requests received during the reporting period.

Certificate Confirmation

KFIN Technologies Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate on 3.04.2026. The certificate confirms that Regulation 74(5) is not applicable to KMS Medisurgi Limited during the quarter ended 31st March, 2026.

The key findings of the certificate include:

• All company shares remain in dematerialised (demat) form
• No requests for re-materialisation were received from shareholders during Q4FY26
• Complete compliance with SEBI depositories regulations maintained

Company and Agent Details

The certificate was signed by Siddharth Kanakia, Managing Director of KMS Medisurgi Limited (DIN: 07595098), and submitted from the company's Mumbai office located at Plot No-297/301 May Building, Marine Lines (East). KFIN Technologies Limited, with its registered office in Hyderabad's Financial District, provided the registrar services and certificate confirmation through Vice President Dnyanesh Gharote.

Regulatory Significance

This quarterly filing demonstrates KMS Medisurgi's continued adherence to SEBI's transparency and compliance requirements. The confirmation that all shares remain in demat form reflects the company's alignment with modern securities market practices and investor preferences for electronic shareholding.

KMS Medisurgi Limited has formally communicated to BSE Limited regarding its exemption from corporate governance reporting requirements for the quarter ended 31st December 2025. The company cited its listing status on the BSE SME Platform as the basis for this exemption under SEBI regulations.

Regulatory Exemption Details

The exemption is granted under Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. This regulation specifically exempts certain categories of listed entities from compliance with corporate governance provisions.

Scope of Corporate Governance Exemptions

Under the regulatory framework, companies listed on SME exchanges are exempt from multiple corporate governance requirements. The exemption covers a comprehensive range of regulations and provisions that typically apply to mainboard listed companies.

The specific regulations from which SME-listed companies are exempt include:

• Regulations 17, 17A, 18, 19, 20, 21, 22, 23, 24, 24A, 25, 26, and 27
• Clauses (b) to (i) and (t) of sub-regulation (2) of regulation 46
• Para C, D and E of Schedule V

Alternative Exemption Criteria

The SEBI regulations also provide exemptions for companies meeting specific financial thresholds. Companies with paid-up equity share capital not exceeding ₹10.00 crores and net worth not exceeding ₹25.00 crores as on the last day of the previous financial year are also eligible for similar exemptions.

Company Communication

KMS Medisurgi Limited's communication to BSE was signed by Managing Director Siddharth Kanakia (DIN: 07595098) on 13th January 2026. The company formally requested BSE to take note of this exemption status for their records.

This regulatory exemption allows SME-listed companies like KMS Medisurgi Limited to focus on their core business operations while maintaining compliance with applicable regulations specific to their listing segment.